Marvaso Giulia, Volpe Stefania, Pepa Matteo, Zaffaroni Mattia, Corrao Giulia, Augugliaro Matteo, Nolè Franco, De Cobelli Ottavio, Jereczek-Fossa Barbara Alicja
Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Cancer Manag Res. 2022 Jan 6;14:89-101. doi: 10.2147/CMAR.S321136. eCollection 2022.
After primary treatment for prostate cancer with either radical prostatectomy or radiotherapy, a significant proportion of patients are at risk of developing metastases. In recent years, a deeper understanding of the underlying biology together with improved imaging techniques and the advent of new therapeutic options including metastases-directed therapies and new drugs have revolutionized the management of low-burden metastatic disease, also known as oligometastatic state. The purpose of this narrative review is to report the recent developments in the management of hormone-sensitive oligometastatic prostate cancer patients.
在采用根治性前列腺切除术或放射疗法对前列腺癌进行初步治疗后，相当一部分患者有发生转移的风险。近年来，对潜在生物学特性的更深入了解、成像技术的改进以及包括转移灶定向治疗和新药在内的新治疗选择的出现，彻底改变了低负荷转移性疾病（即寡转移状态）的管理方式。本叙述性综述的目的是报告激素敏感性寡转移前列腺癌患者管理方面的最新进展。
